New York’s Life Science Disruptors on March 29: Here’s the Agenda

We’re now less than a month away from bringing the New York biotech scene together once again for our annual life sciences event. Today you can have a sneak peek at the details.

On March 29, we’re hosting “New York’s Life Science Disruptors” at the Apella Event Space at the Alexandria Center for Life Science on East 29th Street in Manhattan. It’s an opportunity to get an up-close and candid look at the evolution of the New York biotech scene from the folks committed to moving it forward.

To give you an idea of the change that’s been going on in New York, this will be the third time we’ve hosted this event—but the first time there are high-profile startups, formed by local scientists and armed with big venture funding support, around to participate. Three such startups, all formed since December (Kallyope, Petra Pharma, and Lodo Therapeutics) will be featured, each from three different Manhattan research institutions (Columbia University, Weill Cornell Medical College, and Rockefeller University). You’ll hear the stories of the scientists, entrepreneurs, and investors who created them and about how they came together, the vision for their creations, and what needs to be done to continue the trend. Kicking things off will be Joel Marcus, CEO of Alexandria Real Estate Equities, with an overview of the local scene and the change underway.

Today, we’ve posted the agenda for the event here. You can grab your tickets at this link. Looking forward to seeing you all again at the Apella on March 29.

Author: Ben Fidler

Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.